Efficacy of recombinant bacille Calmette-Guérin vaccine secreting interleukin-15/antigen 85B fusion protein in providing protection against Mycobacterium tuberculosis.
about
Prospects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis?Current efforts and future prospects in the development of live mycobacteria as vaccinesComparison of BCG prime-DNA booster and rBCG regimens for protection against tuberculosis.A new recombinant BCG vaccine induces specific Th17 and Th1 effector cells with higher protective efficacy against tuberculosis.Recombinant BCG as a vaccine vehicle to protect against tuberculosis.Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer.Manipulation of BCG vaccine: a double-edged sword.Correlates of protection induced by vaccination.Tuberculosis vaccines: present and future.Boosting BCG to protect against TB.Recombinant BCG: Innovations on an Old Vaccine. Scope of BCG Strains and Strategies to Improve Long-Lasting MemoryRole of Fused Mycobacterium tuberculosis Immunogens and Adjuvants in Modern Tuberculosis Vaccines.Role of Interferons in the Development of Diagnostics, Vaccines, and Therapy for Tuberculosis.IL-21 inhibits IL-17A-producing γδ T-cell response after infection with Bacillus Calmette-Guérin via induction of apoptosis.Evaluation of Aggregated Ag85B Antigen for Its Biophysical Properties, Immunogenicity, and Vaccination Potential in a Murine Model of Tuberculosis Infection.IL-15 protects antigen-specific CD8+ T cell contraction after Mycobacterium bovis bacillus Calmette-Guérin infection.Next-Generation Vaccines Based on Bacille Calmette-Guérin.Human cord blood γδ T cells expressing public Vγ2 chains dominate the response to bisphosphonate plus interleukin-15.Challenge of developing new tuberculosis vaccines to generate life-long protective immunity.The current status, challenges, and future developments of new tuberculosis vaccines.
P2860
Q28083377-FA28A48F-D64C-4F29-81B9-6C8AE3A3C4C8Q28087077-AF419958-C80A-4859-8A3B-583560E73087Q34290885-79108121-B213-403F-95C4-D779C1BC919FQ34513982-2CE7CB6D-7388-4897-87C5-05C469DEA3B6Q34518560-DC7776FE-7783-44E1-B80C-03D18C70468DQ35215350-94901629-B0C1-4E8A-87FB-AFBF417814BFQ35904315-844113F1-8D33-41FB-8776-AB72EB62FBA7Q37750121-92F13216-5BF3-4B62-AC29-D6FC7E58B72AQ37754908-BBC3E5C6-B23A-40CE-9648-BC106FA8B4DEQ37762830-0E8FD2B2-6D8B-45B5-90A5-2DB210F0BDE4Q38207991-6476BD69-5C36-4091-9FF2-B4F94284CA52Q38209327-A4DD6D5D-06DD-4C33-BB13-A53225318098Q39438318-FC8CDDC7-1F5F-4A92-A9AD-8B8DBE4F760EQ40565511-3D662913-9E72-4CDD-8F7D-48A96E0B9B11Q47100509-2654DE49-7834-4C33-8FE4-33E6D1A710ECQ47953672-2680AFDF-B7AB-4F05-910B-D119A9A61788Q49829375-081FE940-3E28-418A-939C-BAE8EFE008FDQ50927130-E8545C89-7431-4F6C-8E45-50971FBC0915Q51955817-83071087-355D-4492-8236-B900FD6675A7Q52337140-617FC6FE-2C46-429C-B45B-A498A383B41E
P2860
Efficacy of recombinant bacille Calmette-Guérin vaccine secreting interleukin-15/antigen 85B fusion protein in providing protection against Mycobacterium tuberculosis.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Efficacy of recombinant bacill ...... st Mycobacterium tuberculosis.
@en
Efficacy of recombinant bacill ...... st Mycobacterium tuberculosis.
@nl
type
label
Efficacy of recombinant bacill ...... st Mycobacterium tuberculosis.
@en
Efficacy of recombinant bacill ...... st Mycobacterium tuberculosis.
@nl
prefLabel
Efficacy of recombinant bacill ...... st Mycobacterium tuberculosis.
@en
Efficacy of recombinant bacill ...... st Mycobacterium tuberculosis.
@nl
P2093
P2860
P356
P1476
Efficacy of recombinant bacill ...... st Mycobacterium tuberculosis.
@en
P2093
Hisakata Yamada
Kensuke Shibata
Naoya Ohara
Naoyoshi Maeda
Shinichi Yoshida
Takeshi Yamada
Taroh Kinoshita
Worawidh Wajjwalku
Yasunobu Yoshikai
P2860
P304
P356
10.1086/586902
P407
P577
2008-05-01T00:00:00Z